Global Cell & Gene Therapy Industry Shows Strong Growth Across Approvals, Revenue and Deals

February 2026 — Industry News

The global cell and gene therapy (CGT) sector continues to expand, with recent industry data highlighting a combination of strong product revenues, increasing regulatory approvals and growing strategic partnerships. These trends reinforce the momentum of advanced therapies addressing oncology, rare diseases and other high-unmet medical needs.

According to a recent market overview, the industry has achieved 46 U.S. Food and Drug Administration (FDA)-approved therapies to date, reflecting accelerated approvals in both cell-based and gene-based modalities. Among leading products, Zolgensma and Yescarta have each generated more than USD 1 billion in annual sales, underscoring the commercial viability of advanced therapies originally developed to treat spinal muscular atrophy and hematologic cancers, respectively.

Photo by Logan Gutierrez Unsplash

In addition to blockbuster revenues, the report notes over USD 2 billion in strategic deals between biopharmaceutical companies and technology developers, including licensing agreements, platform collaborations and manufacturing partnerships — a sign that major players continue to invest in long-term platform technologies and pipeline diversification.

Industry observers say this combination of market adoption, regulatory success, and financing activity illustrates the maturation of the CGT ecosystem. As more therapies advance through late-stage clinical trials and regulatory pathways, analysts expect continued expansion of both therapeutic options and commercial opportunities globally.

Photo by Lucas Vasques on Unsplash

Source: Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals — Yahoo! Finance / Industry Report (Published recently)